We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

81 hedge funds and large institutions have $386M invested in Oruka Therapeutics in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

18% more capital invested

Capital invested by funds: $326M → $386M (+$59.9M)

14% more funds holding

Funds holding: 71 → 81 (+10)

7.08% more ownership

Funds ownership: 84.87% → 91.96% (+7.1%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
25
Increased
27
Reduced
14
Closed
15
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.9M
2
Mercer Global Advisors
Mercer Global Advisors
Colorado
+$8.88M
3
DTC
Deep Track Capital
Connecticut
+$4.94M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.7M
5
Franklin Resources
Franklin Resources
California
+$3.05M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$3.97M
2
JFG
Jefferies Financial Group
New York
-$3.54M
3
Morgan Stanley
Morgan Stanley
New York
-$3.33M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.29M
5
Goldman Sachs
Goldman Sachs
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Silverarc Capital Management
Massachusetts
$1.85M +$1.72M +165,389 New
ACM
27
ADAR1 Capital Management
Texas
$1.6M +$104K +10,000 +8%
CS
28
Candriam SCA
Luxembourg
$1.31M – – –
UBS Group
29
UBS Group
Switzerland
$1.24M +$800K +76,763 +227%
Barclays
30
Barclays
United Kingdom
$1.02M +$165K +15,831 +21%
Charles Schwab
31
Charles Schwab
California
$942K +$713K +68,394 +438%
Aberdeen Group
32
Aberdeen Group
United Kingdom
$879K +$817K +78,380 New
BGI
33
B Group Inc
Texas
$841K +$175K +16,785 +29%
Goldman Sachs
34
Goldman Sachs
New York
$810K -$1.79M -171,950 -70%
IC
35
Ikarian Capital
Texas
$769K -$1.11M -106,426 -61%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$758K +$705K +67,645 New
JFG
37
Jefferies Financial Group
New York
$729K -$3.54M -340,038 -84%
KCM
38
Kennedy Capital Management
Missouri
$728K -$8.58K -823 -1%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$712K +$662K +63,509 New
Toronto Dominion Bank
40
Toronto Dominion Bank
Ontario, Canada
$654K – – –
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$591K +$102K +9,828 +23%
TD Asset Management
42
TD Asset Management
Ontario, Canada
$514K – – –
N
43
Nuveen
North Carolina
$396K +$368K +35,313 New
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$381K -$3.29M -316,074 -90%
Two Sigma Investments
45
Two Sigma Investments
New York
$363K +$110K +10,511 +48%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$320K +$298K +28,570 New
Deutsche Bank
47
Deutsche Bank
Germany
$217K +$202K +19,361 New
BFM
48
Boothbay Fund Management
New York
$213K -$361K -34,612 -65%
Bank of America
49
Bank of America
North Carolina
$211K +$146K +13,986 +288%
Wells Fargo
50
Wells Fargo
California
$196K +$182K +17,455 New
1
2
3 4

ORKA Hedge Fund Activity: Q2 2025 in Review

81 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2025, worth a combined $386M — up 18% from $326M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ORKA positions and 15 closed out — a net gain of 10 holders — while 27 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was Redmile Group, exiting entirely with an estimated $3.97M sold.

  • 81 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2025, up from 71 in Q1 2025.
  • Funds reported $386M of Oruka Therapeutics stock for Q2 2025, up 18% quarter-over-quarter.
  • 25 funds opened new Oruka Therapeutics positions in Q2 2025 and 15 closed out, a net change of +10 holders.
  • The largest Oruka Therapeutics buyer in Q2 2025 was BlackRock, an estimated $12.9M added.
  • The largest Oruka Therapeutics seller in Q2 2025 was Redmile Group, an estimated $3.97M sold.

Based on aggregated 13F filings for Q2 2025.